{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:05Z","timestamp":1792612265124,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Tumor cell expression of major histocompatibility complex (MHC) class I is required for antigen presentation and adaptive immune recognition. Absent or diminished MHC class I expression is thought to contribute to immunotherapeutic resistance in some epithelial tumors but has not been previously studied in cervical and vulvar carcinoma. Given that anti\u2013programmed cell death 1 (PD-1) checkpoint inhibition is deployed for programmed cell death ligand 1 (PD-L1)-positive recurrent and metastatic cervical squamous carcinomas, identifying tumors with loss of MHC class I is of clinical interest to optimize the selection of immunotherapeutic candidates. Immunohistochemistry for PD-L1 and MHC class I combined A, B, and C heavy chains (MHC class I) was assessed in 58 human papillomavirus\u2013associated cervical and vulvar lesions, including 27 squamous intraepithelial lesions (SILs) and 31 invasive squamous cell carcinoma (SCC). Although 84% of SCC and 22% of SIL were PD-L1-positive, 35.5% (11\/31) of SCC and 18.5% (5\/27) of SIL also showed clonal or complete loss of MHC class I. Loss of MHC class I expression was more common in PD-L1-positive (10\/26, 38%) versus PD-L1-negative SCC (1\/5, 20%). In summary, over one third of human papillomavirus\u2013associated cervical and vulvar SCC show clonal or complete loss of MHC class I expression, including many PD-L1-positive cases. This suggests that the efficacy of checkpoint inhibitors targeting the PD-1\/PD-L1 axis may be limited in a subset of cervical and vulvar squamous neoplasms due to an impaired ability to engage with the adaptive immune system related to loss of MHC class I expression.<\/jats:p>","DOI":"10.1097\/pas.0000000000001506","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T23:51:10Z","timestamp":1591228270000},"page":"1184-1191","source":"Crossref","is-referenced-by-count":31,"title":["Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia"],"prefix":"10.1097","volume":"44","author":[{"given":"Megan E.","family":"Dibbern","sequence":"first","affiliation":[{"name":"Department of Pathology, Division of Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Bullock","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor M.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Stoler","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R4-20230922","first-page":"5955","article-title":"Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research","volume":"37","author":"Gadducci","year":"2017","journal-title":"Anticancer Res"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 Study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000491090","article-title":"Pembrolizumab in recurrent squamous cell carcinoma of the vulva: case report and review of the literature","volume":"84","author":"Shields","year":"2019","journal-title":"Gynecol Obstet Invest"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front Immunol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nri3084","article-title":"Towards a systems understanding of MHC class I and MHC class II antigen presentation","volume":"11","author":"Neefjes","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"R10-20230922","first-page":"4785098","article-title":"MHC class 1 and PDL-1 status of primary tumor and lymph node metastatic tumor tissue in gastric cancers","author":"Erdogdu","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.18632\/oncotarget.23469","article-title":"HLA class I loss and PD-L1 expression in lung cancer: Impact on T-cell infiltration and immune escape","volume":"9","author":"Perea","year":"2018","journal-title":"Oncotarget"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00262-019-02373-1","article-title":"Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy","volume":"68","author":"Friedrich","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-019-02341-9","article-title":"MHC class-I downregulation in PD-1\/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series","volume":"68","author":"Ugurel","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1399-0039.1993.tb01981.x","article-title":"HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix","volume":"41","author":"Torres","year":"1993","journal-title":"Tissue Antigens"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ijc.28713","article-title":"Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy","volume":"135","author":"Van Esch","year":"2014","journal-title":"Int J Cancer"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenviron"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"16956","DOI":"10.1038\/s41598-017-17034-5","article-title":"Assessment of concordance between 22C3 and SP142 immunohistochemistry assays regarding PD-L1 expression in non-small cell lung cancer","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/his.13723","article-title":"PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy","volume":"74","author":"Chinn","year":"2019","journal-title":"Histopathology"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-019-0433-3","article-title":"Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia","author":"Curley","year":"2020","journal-title":"Mod Pathol"},{"key":"R23-20230922","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9014","article-title":"Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: preliminary phase I\/II results of ECHO-202\/KEYNOTE-037","volume":"35","author":"Gangadhar","year":"2017","journal-title":"J Clin Oncol"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/ijms18061331","article-title":"PD-1\/PD-L1 blockade therapy for tumors with downregulated MHC class I expression","volume":"18","author":"\u0160mahel","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.4049\/jimmunol.1900475","article-title":"Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression","volume":"203","author":"Kriegsman","year":"2019","journal-title":"J Immunol"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"7680","DOI":"10.1038\/s41598-019-44206-2","article-title":"Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients","volume":"9","author":"Yoo","year":"2019","journal-title":"Sci Rep"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1038\/s41598-017-03295-7","article-title":"High-risk human papillomavirus E7 alters host DNA methylome and represses HLA-E expression in human keratinocytes","volume":"7","author":"Cicchini","year":"2017","journal-title":"Sci Rep"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"42929","DOI":"10.1038\/srep42929","article-title":"Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer","volume":"7","author":"Aust","year":"2017","journal-title":"Sci Rep"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.7150\/jca.34471","article-title":"Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells","volume":"10","author":"Sun","year":"2019","journal-title":"J Cancer"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41590-019-0578-8","article-title":"Genome-wide CRISPR\u2013Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1","volume":"21","author":"Crowther","year":"2020","journal-title":"Nat Immunol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00428-018-2364-7","article-title":"PD-L1 receptor expression in vulvar carcinomas is HPV-independent","volume":"473","author":"Choschzick","year":"2018","journal-title":"Virchows Arch"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:57:22Z","timestamp":1695423442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001506"}},"subtitle":["A Potential Mechanism of Resistance to Checkpoint Inhibition"],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001506","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}